Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

BACKGROUND: Cystic fibrosis (CF) pulmonary exacerbations can be serious respiratory events and reduction in exacerbation rate or risk are important efficacy endpoints for CF therapeutic trials. Variability in exacerbation diagnoses and treatment have led drug developers to employ “objective” exacerb...

Descripción completa

Detalles Bibliográficos
Autores principales: VanDevanter, Donald R., Hamblett, Nicole Mayer, Simon, Noah, McIntosh, Joseph, Konstan, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Cystic Fibrosis Society. Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362840/
https://www.ncbi.nlm.nih.gov/pubmed/32682670
http://dx.doi.org/10.1016/j.jcf.2020.07.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362840/
https://www.ncbi.nlm.nih.gov/pubmed/32682670
http://dx.doi.org/10.1016/j.jcf.2020.07.008

Ejemplares similares